Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.37 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15063625 | 0.81 | CHRM2 (0.43) | S1PR1ALDH1A1KDM4E | |
| SCHEMBL15063632 | 0.79 | CNR2 (0.41) | SCN9ATRPA1FFAR4 | |
| SCHEMBL456578 | 0.79 | SCN9A (0.48) | S1PR1SCN9ATRPA1FFAR4ALOX5AP | |
| SCHEMBL455625 | 0.78 | SCN9A (0.44) | S1PR1SCN9ATRPA1FFAR4ALOX5AP | |
| SCHEMBL457646 | 0.78 | SCN9A (0.44) | S1PR1SCN9ATRPA1FFAR4ALOX5AP | |
| SCHEMBL458833 | 0.78 | SCN9A (0.44) | S1PR1SCN9ATRPA1FFAR4ALOX5AP | |
| SCHEMBL457764 | 0.78 | SCN9A (0.44) | S1PR1SCN9ATRPA1FFAR4ALOX5AP | |
| SCHEMBL456651 | 0.78 | NISCH (0.41) | L3MBTL1 | |
| SCHEMBL15063817 | 0.77 | PTPRC (0.37) | TRPA1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL455774 | 0.75 | PRKDC (0.42) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3045450-A1 | INTERMEDIATE COMPOUNDS IN A PROCESS FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO., LTD. (JP) | 2016-07-20 | — | — | EP | disclosed |
| EP-2614053-B1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATES THEREOF | SUMITOMO CHEMICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-9040709-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-25 | — | — | US | disclosed |
| US-8884010-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | S1PR1 3705/4885SCN9A 4789/4885TRPA1 3483/4885 |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | S1PR1 3705/4885SCN9A 4789/4885TRPA1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.